Microbial oil and application thereof

By constructing a recombinant cythedritic strain with high yield of DHA, extracting microbial fats rich in DHA, the problem of obtaining Omega-3 fatty acids was solved, and the efficient source of Omega-3 fatty acids was achieved, which significantly improved the content and location distribution of DHA, and effectively prevented it. and treat leukopenia.

CN118909687APending Publication Date: 2024-11-08SHANTOU UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410937666.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-12
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Omega-3 fatty acids, especially EPA and DHA, are mainly derived from marine organisms, making them difficult to obtain and expensive in inland areas. The human body's efficiency in converting ALA into EPA and DHA is not high, making it difficult to meet health needs.

Method used

By constructing a recombinant cythedritic strain with high yield of DHA, using DGAT2.3 gene knockout and DGATam gene insertion, DGATam enzyme with high affinity for DHA-CoA was obtained, and microbial fats rich in DHA were fermented and extracted, thereby increasing the content of DHA and Position distribution to form an efficient source of Omega-3 fatty acids.

Benefits of technology

The proportion of Omega-3 polyunsaturated fatty acids in the obtained microbial oil triglycerides is significantly higher than that of traditional algae oil and fish oil. It can effectively prevent and treat leukopenia caused by organic solvents, and has the same or even better properties as deep-sea fish oil. effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909687A_ABST
    Figure CN118909687A_ABST
Patent Text Reader

Abstract

The invention relates to microbial oil and application thereof. The microbial oil is obtained by extraction and separation of a recombinant schizochytrium limacinum strain, the recombinant schizochytrium limacinum strain is subjected to DGAT2.3 gene knockout and DGATam gene insertion, the nucleotide sequence of the DGATam gene is as shown in SEQ ID No: 1, and the nucleotide sequence of the DGAT2.3 gene is as shown in SEQ ID No: 2. Omega-3 type polyunsaturated fatty acid in triglyceride contained in the microbial oil accounts for 40-70% of the total fatty acid mass, and experiments prove that the microbial oil can have a good effect in prevention and treatment of leucopenia caused by organic solvents, and has the same or even better efficacy as deep sea fish oil.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of compositions of organic active ingredients, in particular to microbial oil and fat and application thereof. Background Art

[0002] Omega-3 is a polyunsaturated fatty acid that has many benefits for human health. There are three main types of omega-3 fatty acids: alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA).

[0003] ALA is a plant-derived omega-3 fatty acid that is mainly found in foods such as flaxseed oil, chia seeds, and walnuts.

[0004] EPA is mainly derived from marine organisms, such as deep-sea fish oil and certain fish. It has many health benefits for the human body, such as anti-inflammatory, lowering blood lipids, and preventing cardiovascular diseases.

[0005] DHA is also an omega-3 fatty acid from marine organisms, especially rich in the brain and eyes. It plays an important role in brain development, vision protection and cognitive function.

[0006] Omega-3 fatty acids have a wide range of effects on human health, including reducing the risk of cardiovascular disease, reducing inflammation, improving cognitive function, protecting vision, etc. Therefore, maintaining adequate Omega-3 intake is very important for maintaining health. Since the human body cannot synthesize enough Omega-3 fatty acids on its own, it needs to be obtained through diet or supplements. However, EPA and DHA are mainly derived from marine organisms and are difficult to obtain inland areas, resulting in their high prices. The human body can convert the more readily available ALA into EPA and DHA, but the conversion efficiency is not high. Summary of the invention

[0007] The purpose of the present invention is to disclose a microbial oil and its application to solve one or more technical problems existing in the prior art and provide at least one beneficial option or create conditions.

[0008] The first aspect of the present invention is to provide a microbial oil.

[0009] The second aspect of the present invention is to provide a method for preparing the microbial oil described in the first aspect of the present invention.

[0010] The third aspect of the present invention is to provide the use of the microbial oil described in the first aspect of the present invention in the preparation of a drug for preventing and treating leukopenia.

[0011] The microbial oil of the first aspect of the present invention is extracted and separated from a recombinant Schizochytrium strain, wherein the recombinant Schizochytrium strain is subjected to DGAT2.3 gene knockout and DGAT am Gene insertion, the DGAT am The nucleotide sequence of the gene is shown in SEQ ID No: 1, and the nucleotide sequence of the DGAT2.3 gene is shown in SEQ ID No: 2. The recombinant Schizochytrium strain is knocked out so that the DGAT2.3 enzyme with low affinity for DHA-CoA is underexpressed, and the DGAT am Gene acquired DGAT with high affinity for DHA-CoA am Enzyme, thereby constructing a recombinant Schizochytrium strain with high DHA production. The obtained recombinant Schizochytrium strain is further used for fermentation and extraction to obtain microbial oils rich in DHA.

[0012] In some application embodiments of the first aspect of the present invention, the separated microbial lipids include triglycerides and phospholipids.

[0013] In some application embodiments of the first aspect of the present invention, omega-3 polyunsaturated fatty acids in the triglycerides account for 40 to 70% of the total fatty acids.

[0014] In some application embodiments of the first aspect of the present invention, the proportion of omega-3 polyunsaturated fatty acids at the sn-3 position of the triglycerides is 30-40%, which is significantly higher than the proportion of omega-3 polyunsaturated fatty acids at the sn-3 position of original algae oil and fish oil.

[0015] The preparation method described in the second aspect of the present invention comprises the following steps:

[0016] 1) inoculating the recombinant Schizochytrium strain into a fermentation medium and culturing for 72 hours;

[0017] 2) centrifugation of the fermentation liquid to obtain wet cells;

[0018] 3) Extract oil from wet cells with chloroform, methanol and water in sequence;

[0019] 4) Separating the obtained oil by thin layer chromatography to retain triglycerides, thereby obtaining the microbial oil.

[0020] The application described in the third aspect of the present invention refers to that the microbial oil can prevent and treat blood leukopenia, and can be used to prepare a drug for preventing and treating blood leukopenia. The blood leukopenia is a blood leukopenia caused by an organic solvent, and the organic solvent includes formaldehyde, benzene, and a mixture of any proportion of benzene compounds.

[0021] In some application embodiments of the third aspect of the present invention, the effective dose of the microbial oil is 3 to 200 mg / kg body weight per day, preferably in the range of 20 to 150 mg / kg body weight per day, and optimally 100 mg / kg body weight per day.

[0022] In some application embodiments of the third aspect of the present invention, the dosage form of the drug is one of ointment, gel, drops, suppository or capsule.

[0023] Compared with the existing detection technology, the present invention has the following advantages:

[0024] 1. Experiments have shown that oils with high DHA content can play a good role in preventing and treating leukopenia caused by organic solvents.

[0025] 2. The microbial oil obtained from the recombinant Schizochytrium strain can have the same or even better effects as deep-sea fish oil. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 It is a bar graph showing the effect of microbial oil on the survival of mice poisoned by benzene;

[0027] Figure 2 It is a line graph of the effect of microbial oil on the weight change of mice poisoned by benzene;

[0028] Figure 3 This is a bar graph showing the effect of microbial oil feeding dose on the survival of mice poisoned by benzene;

[0029] Figure 4 It is a line graph showing the effect of microbial oil feeding dose on the weight change of mice poisoned by benzene;

[0030] Figure 5 This is a bar graph showing the effect of microbial oil feeding dose on the leukocytes of mice poisoned by benzene;

[0031] Figure 6 This is a bar graph showing the effects of microbial oil feeding doses on red blood cells in mice poisoned by benzene. DETAILED DESCRIPTION

[0032] The following examples further illustrate the content of the present invention, but should not be construed as limiting the present invention. Without departing from the spirit and essence of the present invention, modifications and substitutions made to the methods, steps or conditions of the present invention all belong to the scope of the present invention.

[0033] Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art.

[0034] The molecular biology experimental methods not specifically described in the following examples are all carried out with reference to the Molecular Cloning Experiment Guide (3rd edition) or in accordance with the kits and product instructions; the biological materials of the kits, unless otherwise specified, can be obtained from commercial channels.

[0035] Example 1: Preparation of recombinant Schizochytrium oil

[0036] 1) knocking out the DGAT2.3 gene as shown in SEQ ID No: 2 in Schizochytrium to construct a Schizochytrium DGAT knockout;

[0037] 2) containing DGAT as shown in SEQ ID No: 1 am The overexpression vector of the gene was electrotransfected into the knockout to construct DGAT am Recombinant Schizochytrium strains with heterologous overexpression of genes;

[0038] 3) The recombinant Schizochytrium strain was inoculated into a fermentation medium and cultured for 72 hours, the fermentation broth was centrifuged to obtain wet cells, oil was extracted with chloroform-methanol-water, and triglycerides were separated by TLC to obtain the recombinant Schizochytrium oil.

[0039] Example 2: Comparison of analysis of recombinant Schizochytrium oil and existing DHA

[0040] The differences among deep-sea fish oil, wild-type Schizochytrium algae oil and the recombinant Schizochytrium algae oil obtained in Example 1 were analyzed by gas chromatography-mass spectrometry (GC-MS). The results are shown in Table 1.

[0041] Table 1. Distribution of n-3 PUFA on triglycerides (% of total n-3 PUFA)

[0042]

[0043] It can be seen that the proportion of omega-3 polyunsaturated fatty acids in the sn-3 position of the recombinant Schizochytrium oil is much higher than that of deep-sea fish oil or wild-type Schizochytrium oil. Human triglyceride esterase has positional isomer selectivity for TAG, which mainly hydrolyzes the ester bonds of TAG sn-1 and sn-3, converting a large amount of saturated fatty acids into acyl-CoA for the synthesis and utilization of phospholipids. Therefore, increasing the DHA content of the sn-3 position of oil TAG helps to improve its nutritional value.

[0044] Example 3: Comparison of the effects of microbial lipids and fish oils in preventing and treating leukopenia induced by organic solvents

[0045] 1.1 Main reagents and materials

[0046] Test animals: SPF-grade KM male mice, 28 to 41 days old, purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd., license number: SCXK (Beijing) 2021-0011.

[0047] Tested oils: oil extracted from recombinant Schizochytrium strain (hereinafter referred to as "algae oil") and fish oil; after chloroform-methanol extraction, methyl esterification and gas chromatography analysis, the fatty acid composition and polyunsaturated fatty acids of the above oils are shown in Table 2:

[0048] Table 2 Fatty acid composition of fish oil and algae oil (%)

[0049]

[0050] Chemical reagents, consumables and instruments: benzene, disodium hydrogen phosphate heptahydrate, 2mL centrifuge tubes, 10mL centrifuge tubes, medical sterile 1mL disposable syringes, EDTA-K2 vacuum blood collection tubes, analytical balance, routine blood analyzer and measuring cylinder, etc.

[0051] 1.2 Experimental methods

[0052] 1.2.1. Rearing and handling

[0053] A total of 80 8-day-old KM healthy male mice (weighing 20-25g) were temporarily kept for 3 days before the experiment to allow them to eat freely to adapt to the environment (the feed did not contain DHA). The mice were evenly divided into four groups: blank group (soybean oil), benzene treatment group (soybean oil-benzene), algae oil-benzene group and fish oil-benzene group. The experiment was divided into a nutritional fortification stage (1st to 14th day) and a benzene treatment stage (15th to 28th day). The specific treatment process is as follows:

[0054] (1) Nutritional enhancement phase (days 1 to 14): Feed and nutrients were renewed every other day at the same time. The blank group and the benzene treatment group were fed 100 mL of water at a fixed time every other day, and the algae oil-benzene group and the fish oil-benzene group were fed algae oil and fish oil at a dose of 100 mg DHA / kg BW·d.

[0055] (2) Benzene treatment experimental phase (Days 15-28): Benzene treatment began on Day 15. Except for the blank solvent group, mice in other groups were intraperitoneally injected with a 10% benzene solution once every two days at a dose of 150 mg / kg / d for a total of 7 injections.

[0056] 2.2. Blood sample collection

[0057] After the mice have completed the feeding and handling process, blood samples were collected on the 28th day. The mice were placed in a sealed container filled with chloroform for anesthesia. When the mice's mobility was significantly reduced, they were taken out and blood was collected from the eye sockets with tweezers. The blood samples were stored in EDTA anticoagulant blood collection tubes, which were shaken to allow the blood samples to fully contact and mix with the anticoagulant, and marked on the tube label.

[0058] 2.3. Routine blood test

[0059] After the blood sample was collected, it was immediately sent to the First Affiliated Hospital of Shantou University Medical College for routine blood tests to determine the levels of white blood cells, red blood cells, etc. The instrument model was Mindray's fully automatic blood cell analyzer BC-5000.

[0060] Data processing

[0061] One-way ANOVA was used for significance analysis, followed by multiple comparison test. P < 0.05 was considered significant; data are expressed as mean ± standard deviation.

[0062] 3. Implementation Effect

[0063] Effects of algal oil and fish oil on the survival and growth of mice poisoned by benzene

[0064] Depend on Figure 1 It can be seen that a 150mg / kg·d benzene injection dose can cause 50% of mice to die, but after being fortified with 50mgDHA / kg·d fish oil, the mortality rate of mice dropped by half to only 25%. However, after being fortified with 50mgDHA / kg·d algae oil, the mortality rate of mice poisoned by benzene was further reduced to 0.

[0065] Depend on Figure 2 It can be seen that fish oil and algae oil had no significant promoting effect on the growth of mice during the nutritional fortification stage (1-14 days), but the effects of the two were significantly different during the benzene treatment stage. The normalized body weight of the fish oil-benzene group was significantly lower than that of the algae oil-benzene group. The body weight of the algae oil-benzene group was greater than that of the fish oil-benzene group and the benzene treatment group throughout the benzene treatment stage.

[0066] 3.2. Effects of DHA from fish oil and algae oil on peripheral blood composition of mice poisoned by benzene

[0067] As shown in Table 3, after benzene treatment, the number of peripheral blood leukocytes in the benzene-treated group decreased by almost 40% compared with the blank group, while the number of red blood cells increased significantly by 15%. Although the fish oil-benzene group increased the number of leukocytes, there was no significant difference from the benzene-treated group, which shows that fish oil did not successfully treat leukopenia caused by benzene poisoning. In contrast, the nutritional fortification treatment of the algae oil-benzene group significantly increased the number of leukocytes in the benzene-poisoned mice from 4.19×10 9The number / L increased to 6.25×10 9 The above results show that algae oil has a significant therapeutic effect on leukopenia caused by benzene, while fish oil has no therapeutic effect.

[0068] Table 3 Effects of fish oil and algae oil DHA on the number of peripheral blood leukocytes and erythrocytes in mice poisoned by benzene

[0069]

[0070] The results of leukocyte classification counts are shown in Table 4. The analysis results show that benzene treatment alone significantly reduced the number of neutrophils, lymphocytes, eosinophils and monocytes in leukocytes. Fish oil nutritional fortification did not significantly change the composition of leukocytes in mice poisoned by benzene. However, similar to the changes in the total number of leukocytes, the addition of algae oil significantly changed the composition of leukocytes in mice poisoned by benzene. The above results once again verified the therapeutic effect of algae oil on leukocytopenia.

[0071] Table 4 Effects of fish oil and algae oil DHA on the number of peripheral blood leukocytes in mice poisoned by benzene

[0072]

[0073] Example 2: Effect of microbial lipid concentration on the preventive effect of leukopenia

[0074] 2.1. Animals and reagents and consumables: Same as in Example 1.

[0075] 2.2. Implementation methods

[0076] 2.2.1.DHA dosage design

[0077] According to the standards of the World Health Organization, the recommended daily DHA dose for healthy adults is about 220 mg. This experiment assumes that adults consume 220 mg of DHA per day, and uses the body surface area normalization method (BSA) to convert the human dose into the animal dose. That is, based on the equivalent dose ratio of 0.0026 between humans and mice converted by body surface area, it can be calculated that the DHA dose for mice is 28.6 mg / kg·d. Because the experiment needs to explore the minimum and optimal supplementation levels, the DHA intake of mice converted from the recommended daily DHA intake was adjusted, and each group was set as: 10 mg / kg·d for the low-dose group, 50 mg / kg·d for the medium-dose group, and 100 mg / kg·d for the high-dose group.

[0078] 2.2.2. Animal grouping, feeding and injection

[0079] SPF male KM mice (weight 18-22 g) were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., license number: SCXK (Beijing) 2021-0011. After 3 days of adaptation to the feed, 100 mice were randomly divided into 5 groups according to body weight, including a blank group, a benzene poisoning group, 10 mg DHA / kg·d (low-dose group), 50 mg DHA / kg·d (medium-dose group), and 100 mg DHA / kg·d (high-dose group).

[0080] DHA nutritional fortification: Days 1 to 14 were the DHA nutritional fortification period. The blank group and the benzene poisoning group were given an equal volume of water, while each DHA dose group was orally given DHA once every two days for a total of 7 times. Body weight was recorded every 2 days.

[0081] Benzene treatment period: From the 15th day, except for the blank group, the remaining groups continued to be given benzene treatment while continuing to strengthen nutrition. The mice in the benzene poisoning group, low-dose group, medium-dose group and high-dose group were intraperitoneally injected with benzene solution (dose 0.15g / kg·BW·day, with water as solvent) every other day. The blank group was intraperitoneally injected with an equal amount of sterile water every other day. The body weight was recorded every 2 days. On the 28th day of the experiment, the eyeballs were removed and anticoagulated blood was collected for blood cell composition analysis. The specific method is the same as in Example 1.

[0082] 2.2.3. Blood routine test

[0083] After the blood sample was collected, it was immediately sent to the First Affiliated Hospital of Shantou University Medical College for routine blood tests to determine the levels of white blood cells, red blood cells, etc. The instrument model was Mindray's fully automatic blood cell analyzer BC-5000.

[0084] Data processing

[0085] One-way ANOVA was used for significance analysis, followed by multiple comparison test. P < 0.05 was considered significant; data are expressed as mean ± standard deviation.

[0086] 2.3. Implementation results

[0087] Figure 3 The results showed that both the low-dose and medium-dose groups of DHA could significantly reduce the mortality of benzene-poisoned mice, from 50% to 1. Figure 3 ) was reduced to 0, while the high-dose group could also reduce the mortality rate, but the mortality rate was still 12.5%. From the mortality rate, it can be seen that the effects of the low-dose group and the medium-dose group are better than the high-dose group. The algae oil DHA feeding dose had no significant effect on the body weight of the surviving mice (see Figure 4 ).

[0088] Figure 5The results of the changes in the number of white blood cells shown in the figure show that the low-dose group and the high-dose group did not significantly improve the leukopenia caused by benzene toxicity, but the medium-dose group showed a good therapeutic effect. The changes in the number of red blood cells in benzene poisoning also confirmed the good therapeutic effect of the medium-dose group, whose red blood cell count was significantly lower than that of the poisoning group but had no significant difference with normal mice (see Figure 6 ). According to the reverse calculation of BSA, the effective dose of algae oil for human body is 3-200 mg / kg body weight per day, the preferred dose range is 20-150 mg / kg body weight per day, and the optimal dose is 100 mg / kg body weight per day.

[0089] It will be apparent to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above and that the present invention can be implemented in other specific forms without departing from the spirit or essential features of the present invention. Therefore, the embodiments should be considered exemplary and non-restrictive in all respects, and the scope of the present invention is defined by the appended claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims be included in the present invention.

Claims

1. A microbial oil, characterized in that: It is extracted and separated from a recombinant Schizochytrium strain, wherein the recombinant Schizochytrium strain is subjected to DGAT2.3 gene knockout and DGAT am Gene insertion, the DGAT am The nucleotide sequence of the gene is shown in SEQ ID No: 1, and the nucleotide sequence of the DGAT2.3 gene is shown in SEQ ID No:

2.

2. The microbial oil according to claim 1, characterized in that The separated microbial lipids include triglycerides and phospholipids.

3. The microbial oil according to claim 2, characterized in that: The omega-3 polyunsaturated fatty acids in the triglycerides account for 40 to 70% of the total fatty acid mass.

4. The microbial oil according to claim 3, characterized in that: The omega-3 polyunsaturated fatty acids of the triglyceride located at the sn-3 position account for 30-40%.

5. The method for preparing the microbial oil according to any one of claims 1 to 4, characterized in that: Includes steps: 1) inoculating the recombinant Schizochytrium strain into a fermentation medium and culturing for 72 hours; 2) centrifugation of the fermentation liquid to obtain wet cells; 3) Extract oil from wet cells with chloroform, methanol and water in sequence; 4) Separating the obtained oil by thin layer chromatography to retain triglycerides, thereby obtaining the microbial oil.

6. Use of the microbial oil according to any one of claims 1 to 4 in the preparation of a drug for preventing or treating leukopenia.

7. The use according to claim 6, characterized in that: The leukopenia is caused by organic solvents including formaldehyde or benzene compounds.

8. The use according to claim 6, characterized in that: The effective dose of the microbial oil contained in the medicine is 3 to 200 mg / kg·d; preferably, the effective dose of the microbial oil is 20 to 150 mg / kg·d; preferably, the effective dose of the microbial oil contained in the medicine is 100 mg / kg·d.

9. The use according to claim 6, characterized in that: The drug further contains a physiologically acceptable carrier or excipient.

10. The use according to claim 9, characterized in that: The dosage form of the drug is one of ointment, gel, drops, suppository or capsule.